Gilead Sciences, Inc.GILD

NasdaqGS•Healthcare•Drug Manufacturers - General

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Price & Volume

Key Metrics at a Glance (as of December 2025)

Market Cap: $154.34B
TTM Revenue: $29.44B
TTM EBITDA: $12.89B
P/E Ratio: 18.1x
Operating Margin: 37.4%
Free Cash Flow: $3.12B

Financial Analysis

Gilead Sciences, Inc. (GILD) reported trailing twelve months (TTM) revenue of $29.44B as of December 2025, which represents a 2.4% increase year-over-year. The company's operating margin has expanded to 37.4% from 32.4% a year ago. In terms of profitability, GILD generated $8.51B in net income. Valuation-wise, the stock trades at a P/E ratio of 18.1x and a Price-to-Sales (P/S) ratio of 5.2x. The company generated $3.12B in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.